Prostate Cancer
Conditions
Interventions
After registration, the following drugs will be administered: Degarelix: Initial dose of 240mg administered subcutaneously at two abdominal sites (120mg per site). From the second dose onward, 80mg w
Sponsors
Gifu University
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Male prostate cancer patients aged 20 years or older with bone metastases at the time of informed consent 2. Prostate cancer patients with 4 or more bone metastases at the time of registration 3. Patients who can take apalutamide orally 4. Patients who can receive degarelix and denosumab administration 5. Patients with an expected survival of at least 6 months at the time of informed consent 6. Patients with Performance Status (PS) 0 or 1 at the time of informed consent 7. Patients from whom written informed consent for participation in this study can be obtained
Exclusion criteria
Exclusion criteria: 1. Patients with 3 or fewer bone metastases, or patients with visceral metastases other than lung metastases 2. Patients unable to visit the hospital for radiation therapy 3. Patients with osteonecrosis of the jaw at the time of informed consent, or patients with severe dental caries 4. Patients who have received anticancer drug treatment such as docetaxel prior to enrollment in this study 5. Patients who have received radiation therapy (regardless of site) prior to enrollment in this study 6. Patients judged ineligible for participation in this study by the principal investigator or co-investigators at the participating medical institutions of this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-Free Survival (PFS) | — |
Countries
Japan
Contacts
Public ContactTakuya Koie
Gifu University Urology
Outcome results
None listed